Avelumab companion diagnostic- Merck/Pfizer/Dako

Drug Profile

Avelumab companion diagnostic- Merck/Pfizer/Dako

Latest Information Update: 26 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Agilent Technologies; Merck KGaA; Pfizer
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Merkel cell carcinoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 24 Sep 2015 Clinical trials in Merkel cell carcinoma (Diagnosis) in USA (unspecified route)
  • 24 Sep 2015 Clinical trials in Non-small cell lung cancer (Diagnosis) in USA (unspecified route)
  • 24 Sep 2015 Clinical trials in Solid tumours (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top